1. Chassany O, Marquis P, Scherrer B, Read NW, Finger
T, Bergmann JF et al. Validation of a spesific quality
of life questionnaire for functional digestive disorders.
Gut 1999; 44(4):527-533.
2. Talley NJ, Stanghellini V, Heading RC, Koch KL,
Malagelada JR, Tytgat GNJ. Functional
gastroduodenal disorders. Gut 1999; 45:1137-1142.
3. Fernandez L. Indigestion and heartburn. In: Textbook
of Primary Care Medicine. J.Third ed. Mosby Inc, St
Louis, USA; 2001:189-192.
4. Talley Nj. Dyspepsia. Management guidelines for the
millenium. Gut 2002; 50:72-78.
5. Köksal AŞ, Oğuz D, Özden A. Türkiye’de birinci
basamak sağlık kurumlarına başvuran hastalarda
dispepsi görülme sıklığı. Akademik Gastroenteroloji
Dergisi 2008; 7(1):11-17.
6. Erdoğan AF. Dispeptik yakınmaları olan hastalarda
Helicobacter pylori enfeksiyonunun Helicobacter
pylori stool antijen ile saptanması ve tedavinin etkinliğinin değerlendirilmesi. Uzmanlık tezi. Tez danış-
manı Bozdemir N. Çukurova Üniversitesi Tıp Fakültesi Aile Hekimliği AD. Adana, 2003.
7. Türkolmez S, Cayır D, Aydoğan F, Korkmaz M. The
relationship of Helicobacter pylori positivity with age,
sex and ABO/rhesus blood groups in patients with
gastrointestinal complaints in Turkey. Helicobacter
2007; 12:244-250.
8. Erdoğan AF, Turan I, Gereklioğlu Ç, Abacı K. Aile
hekimliği polikliniğinde dispeptik hastalarda
Helicobacter pylori sıklığı. Türk Aile Hek Derg 2008;
12(4):198-202.
9. Fraser A, Delaney B, Moayyedi P. Symptom-based
outcome measures for dyspepsia and GERD Trials: A
Systematic Review. Am J Gastroenterol 2005 Feb;
100(2):442-452.
10. Michael JLS, Kenneth LK. Dispepsi. Health Press
2005, 9-15.
11. Bilgel N. Aile Hekimliği. Medikal Tıp Kitabevi 2006,
247-259.
12. Rabeneck L, Wristers K, Goldstein JL, Eisen G,
Dedhiya SD, Burke TA. Reliability, validity and
responsiveness of severity of dispepsia assessment
(SODA) in a randomized clinical trial of a COX-2-
specific inhibitor and traditional NSAİD therapy. Am
J Gastroenterol 2002; 97(1):32-39.
13. Mutlu ET, Malhan S, Oksuz E, Ersoy K. Dispepsi
Şiddet Ölçeği (SODA) Türkçe Uyarlamasının Geçerlilik ve Güvenilirlik Çalışması. 7. Ulusal Aile Hekimli-
ği Kongresi. Çeşme, 2006.
14. Stewart AL, Hays RD, Ware JEJ. The MOS shortform general health survey: reliability and validity in
a patient population. Med Care 1988; 26:724-735.
15. Ware JE, Sherbourne CD. The MOS 36-item shortform health survey (SF-36). I. Conceptual framework
and item selection. Med Care 1992; 30(6):473-483.
16. McHorney CA, Ware JE, Lu JF, Sherbourne CD. The
MOS 36-item Short-Form Health Survey (SF-36): III.
Tests of data quality, scaling assumptions, and
reliability across diverse patient groups. Med Care
1994; 32(1):40-66.
17. Aydemir Ö. Konsültasyon-liyezon psikiyatrisinde
yaşam kalitesi ölçümü: Kısa Form-36 (SF-36). 3P
Dergisi 1999; 7(2):14-22.
18. Koçyiğit H, Aydemir Ö, Ölmez N, Memiş A. Kısa
Form-36 (SF-36)’nın Türkçe için güvenilirliği ve
geçerliliği: Romatizmal hastalığı olan bir grup hasta
ile çalışma. 34. Ulusal Psikiyatri Kongresi ve Uluslararası Uydu Sempozyumu. İzmir, 29 Eylül-3 Ekim
1998.
19. Tack J, Talley NJ, Camileri M, Holtmann G, Hu
Pinjin, Malagelada JR et al. Fonksiyonel
Gastroduodenal bozukluklar. Gastroenterology Türk-
çe baskı 2006; 2(3):162-178.
20. Drossman A. The Functional Gastrointestinal
Disorders and the Rome III Process. Gastroenterology
2006; 130:1377-1390.
21. Talley NJ, Vakil N. Guidelines for the management of
Dyspepsia. Am J Gastroenterol 2005; 100:2324–2337.
22. Kitapcıoğlu G, Mandıracıoğlu A, Caymaz Bor C, Bor
S. Toplumda gastroözefageal reflü ve dispepsi semptomlarının örtüşmesi. Turk J Gastroenterol 2007;
18(1):14-19.
23. Thomson ABR, Barkun AN, Armstrong D, Chiba N,
White RJ, Daniels S et al. The prevalence of clinically
significant endoscopic findings in primary care
patients with uninvestigated dyspepsia: The Canadian
Adult Dyspepsia Empiric treatment-prompt
endoscopy (CADET-PE) study. Aliment Pharmacol
Ther 2003; 17:1481-1491.
24. Runge MS, Greganti MA. Çevri eds. Ünal S, Demir
M. Netter İç Hastalıkları. Güneş Tıp Kitabevi. 2009,
Bölüm 47:313-318.
25. Mahadeva S, Khean-Lee G. Epidemiology of
functional dyspepsia: A global perspective. World J
Gastroenterol 2006; 12(17):2661-2666.
26. Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer
BL, Talley NJ. Lansoprazole in the treatment of
functional dyspepsia: two double blind, randomized,
placebo-controlled trials. Am J Med 2004; 116:740-
748.
27. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley
NJ. The efficacy of proton pump inhibitors in
nonulcer dyspepsia: a systematic review and
economic analysis. Gastroenterology 2004; 127:1329-
1337.
28. Jeong JJ, Choi MG, Cho YS, Lee SG, Oh JH, Park JM
et al. Chronic gastrointestinal symptoms and quality
of life in the Korean population. World J
Gastroenterol 2008; 14:6388-6394.
29. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ.
Dyspepsia and dyspepsia subgroups: a populationbased study. Gastroenterology 1992; 102:1259-1268.
30. Shaib Y, El-Serag HB. The prevalence and risk
factors of functional dyspepsia in a multiethnic
population in the United States. Am J Gastroenterol
2004; 99:2210-2216.
31. Moayyedi P, Forman D, Braunholtz D, Feltbower R,
Crocombe W, Liptrott M et al. The proportion of
upper gastrointestinal symptoms in the community
associated with Helicobacter pylori, lifestyle factors,
and nonsteroidal anti-inflammatory drugs. Leeds
HELP Study Group. Am J Gastroenterol 2000;
95:1448-1455.
32. Piessevaux H, De Winter B, Louis E, Muls V, De
Looze D, Pelckmans P et al. Dyspeptic symptoms in
the general population: a factor and cluster analysis of
symptom groupings. Neurogastroenterol Motil 2009;
21:378-388.
33. Bektaş M, Çetinkaya H, Çalışkan D, Öztaş E, Akdur
R, Özden A. Park Sağlık Ocağı bölgesinde 15 yaş üstü
nüfusta dispepsi prevalansı. Akademik Gastroenteroloji Dergisi 2007; 6(3):120-126.
34. Özden A, Sivri B. Dyspepsia. Ed. Özden A. Ankara,
Türk Gastroenteroloji Vakfı yayınları. Ajans-Türk
Basın ve Basım A.Ş. 1996; 1-8.
35. Öksüz E, Malhan S. Sağlığa Bağlı Yaşam Kalitesi:
Kalitemetri. Başkent Üniversitesi Yayınları. Ankara
2005.
36. Müezzinoğlu T. Yaşam kalitesi. Üroonkoloji Bülteni
2005; 1:25-29.
37. Fidaner C. Sağlıkta yaşam kalitesi kavramı: Bir giriş
denemesi. Birinci Sağlıkta Yasam Kalitesi Sempozyumu, 2004, Izmir.
38. Okçu N, Yılmaz Ö, Dursun H, Polat G, Gürsan N,
Çayır K. Dispeptik semptomlarla beslenme alışkanlıkları, endoskopik ve histolojik bulgular arasındaki iliş-
ki. Akademik Gastroenteroloji Dergisi 2006;
5(2):110-115.
39. Sayın I, Oğuz AK, Değertekin H. Fonksiyonel
dispepsinin değerlendirilmesinde klinik yaklaşım.
Akademik Gastroenteroloji Dergisi 2008; 7(2):91-95.
40. Talley NJ, Locke GR, Lahr BD, Zinsmeister AR,
Tougas G, Ligozio G et al. Functional dyspepsia,
delayed gastric emptying, and impaired quality of life.
Gut 2006; 55:933-939.
41. Welen K, Faresjo A, Faresjo T. Functional dyspepsia
affects women more than men in daily life: a case-
control study in primary care. Gend Med 2008; 5:62-
73.
42. Haqua M, Wyeth JW, Stace NH, Talley NC, Gren R.
Prevalence, severity and associated features of gastro-
esophageal reflux and dyspepsia: A population-based
study. N Z Med 2000; 113:178.
43. Halling K, Kulich K, Carlsson J, Wiklund I. An
international comparison of the burden of illness in
patients with Dyspepsia. Dig.Dis 2008; 26(3):264-
273.
44. American Gastroenterological Association medical
position statement: evaluation of dyspepsia.
Gastroenterology 2005; 129:1753-1755.
45. NHS Guideline. http://www.nice.org.uk Erişim tarihi:
04.11.2010.
46. Jones MP. Evaluation and treatment of dyspepsia.
Postgard Med J 2003; 79:25-29.
47. Armstrong D, Veldhuyzen SJO, Barkun AN, Chıba N,
Thomson ABR, Smyth S et al. Heartburn-dominant,
uninvestigated dyspepsia: a comparison of ‘PPI-start’
and ‘H2-RA-start’ management strategies in primary
care - the CADET-HR Study. Aliment Pharmacol
Ther 2005; 21:1189–1202.
48. Rabeneck L. Measuring dyspepsia-related health in
randomized trials: the Severity of Dyspepsia
Assessment (SODA) and its use in treatment with
NSAIDs and COX-2-specific inhibitors.
Rheumatology 2003; 42(Suppl.3):32-39.
49. Roberts DN, Miner PB. Safety aspects and rational
use of naproxen+esomeprazole combination in the
treatment of rheumatoid disease. Drug Healthcare and
Patient Safety 2011:3.
50. Halder SL, Locke GR, Talley NJ, Fett SL,
Zinsmeister AR, Melton LJ. Impact of functional
gastrointestinal disorders on health-related quality of
life: a population-based case-control study. Aliment
Pharmacol Ther. 2004; 19(2):233-242.
51. El-Serag HB, Talley NJ. Systematic review: healthrelated quality of life in functional Dyspepsia.
Aliment Pharmacol Ther 2003; 18:387–393.
52. Jeong JJ, Choi MG, Cho YS, Lee SG, Oh JH, Park JM
et al. Chronic gastrointestinal symptoms and quality
of life in the Korean population. World J
Gastroenterol 2008; 14(41):6388-6394.
53. Brun R, Kuo B. Functional Dyspepsia. Ther. Adv.
Gastroenterol 2010; 3(3):145-164.
İletişim:
Yrd.Doç.Dr Cihangir ÖZCAN
Başkent Üniversitesi Ümitköy Polikliniği Mutlukent
Mah. 1963.sok No:17
tel: +90.0533.5224964 fax: +90.312.2364449
mail:cozcan@baskent.edu.t
Thank you for copying data from http://www.arastirmax.com